Nevirapine single-dose (NVP-SD) reduces mother-to-child transmission of HIV type-1 (HIV-1), but frequently induces resistance mutations in the HIV-1 genome. Little is known about drug-resistant HIV-1 variants in the breast milk of women who have taken NVP-SD.
Methods
Blood and breast milk samples of 39 HIV-1-infected Ugandan women were taken 6–12 weeks after NVP-SD intake. Samples were analysed by population sequencing and allele-specific real-time PCR (AS-PCR) with detection limits for NVP-resistant HIV-1 variants (K103N and Y181C) of <1% of the total viral population.
Results
AS-PCR results for both plasma and breast milk were obtained for 19 women who constituted the final study group (HIV-1 subtype frequencies were A1 n=11, D n=5, G n=2 and C n=1). A total of 7 (37%) and 10 (53%) women carried NVP-resistant virus in breast milk and plasma, respectively. Overall, 71% (5/7) women with NVP-resistant HIV-1 in breast milk displayed >1 drug-resistant variant. Resistance in breast milk was higher at week 6 (6/13 samples [46%]) compared with week 12 (1/6 samples [17%]). In total, 10 drug-resistant populations harbouring the K103N and/or Y181C mutation were detected in the 19 breast milk samples; 7 (70%) were caused by resistant minorities (<5% of the total HIV-1 population). In the four women with drug-resistant virus in both plasma and breast milk, the mutation patterns differed between the two compartments.
Conclusions
Minor populations of drug-resistant HIV-1 were frequently found in breast milk of Ugandan women after exposure to NVP-SD. Further studies need to explore the role of minor drug-resistant variants in the postnatal transmission of (resistant) HIV-1.
References
1.
World Health Organization.HIV transmission though breastfeeding: a review of available evidence. Geneva: World Health Organization2004.
2.
GuayL.A., MusokeP., FlemingT.Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet1999; 354: 795–802.
3.
EshlemanS.H., GuayL.A., MwathaA.Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6–8 weeks after single-dose NVP prophylaxis: HIVNET 012. AIDS Res Hum Retroviruses2004; 20: 595–599.
4.
EshlemanS.H., HooverD.R., ChenS.Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis2005; 192: 30–36.
5.
FlysT.S., DonnellD., MwathaA.Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis2007; 195: 711–715.
6.
FlysT.S., McConnellM.S., MatovuF.Nevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmission. J Infect Dis2008; 198: 465–469.
7.
JohnsonJ.A., LiJ.F., MorrisL.Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis2005; 192: 16–23.
8.
LoubserS., BalfeP., ShermanG., HammerS., KuhnL., MorrisL.Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS2006; 20: 995–1002.
9.
PalmerS., BoltzV., MartinsonN.Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci U S A2006; 103: 7094–7099.
10.
LockmanS., McIntyreJ.A.Reduction of HIV-1 drug resistance after intrapartum single-dose nevirapine. Lancet2007; 370: 1668–1670.
11.
FlysT.S., ChenS., JonesD.C.Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. J Acquir Immune Defic Syndr2006; 42: 610–613.
12.
MoorthyA., GuptaA., BhosaleR.Nevirapine resistance and breast milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. PLoS ONE2009; 4: e4096.
13.
KassayeS., LeeE., KantorR.Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: population and clonal sequence analysis. AIDS Res Hum Retroviruses2007; 23: 1055–1061.
14.
LeeE.J., KantorR., ZijenahL.Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine. J Infect Dis2005; 192: 1260–1264.
15.
HudelsonS.E., McConnellM.S., BagendaD.Emergence and persistence of nevirapine resistance in breast milk after single dose nevirapine administration. AIDS2010; 24: 557–561.
16.
KunzA., FrankM., MugenyiK.Persistence of nevirapine in breast milk and plasma of mothers and their children after single-dose administration. J Antimicrob Chemother2009; 63: 170–177.
17.
HauserA., MugenyiK., RoseK.Detection and quantification of minor HIV-1 variants harbouring K103N and Y181C resistance mutations in subtype A and D isolates by allele-specific real-time PCR. Antimicrob Agents Chemother2009; 53: 2965–2973.
John-StewartG., Mbori-NgachaD., EkpiniR.Breastfeeding and transmission of HIV-1. J Acquir Immune Defic Syndr2004; 35: 196–202.
23.
AndreottiM., GuidottiG., GalluzzoC.M.Resistance mutation patterns in plasma and breast milk of HIV-infected women receiving highly-active antiretroviral therapy for mother-to-child transmission prevention. AIDS2007; 21: 2360–2362.
24.
McIntyreJ.A., HopleyM., MoodleyD.Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial. PLoS Med2009; 6: e1000172.
25.
RousseauC.M., NduatiR.W., RichardsonB.A.Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease. J Infect Dis2003; 187: 741–747.
